Drug Profile
Etesevimab - Institute of Microbiology of the Chinese Academy of Sciences/Shanghai Junshi Biosciences
Alternative Names: Anti-SARS-CoV-2 monoclonal antibody - Shanghai Junshi Bioscience; JS 016; LY 3832479; LY-CoV-016; Recombinant human anti-SARS-CoV-2 monoclonal antibody - Shanghai Junshi BioscienceLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Institute of Microbiology of the Chinese Academy of Sciences; Shanghai Junshi Biosciences
- Developer Eli Lilly and Company; Institute of Microbiology of the Chinese Academy of Sciences; Shanghai Junshi Biosciences
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(In volunteers) in USA (IV, Infusion)
- 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(Prevention) in USA (IV, Infusion)
- 28 Jul 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in China (IV, Infusion)